A novel orally available asthma drug candidate that reduces smooth muscle constriction and inflammation by targeting GABA(A) receptors in the lung

We describe lead compound MIDD0301 for the oral treatment of asthma based on previously developed positive allosteric α(5)β(3)γ(2) selective GABA(A) receptor (GABA(A)R) ligands. MIDD0301 relaxed airway smooth muscle at single micromolar concentrations as demonstrated with ex vivo guinea pig tracheal...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Pharm
Main Authors: Forkuo, Gloria S., Nieman, Amanda N., Kodali, Revathi, Zahn, Nicolas M., Li, Guanguan, Rashid Roni, M. S., Stephen, Michael Rajesh, Harris, Ted W., Jahan, Rajwana, Guthrie, Margaret L., Yu, Olivia B., Fisher, Janet L., Yocum, Gene T., Emala, Charles W., Steeber, Douglas A., Stafford, Douglas C., Cook, James M., Arnold, Leggy A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5954213/
https://ncbi.nlm.nih.gov/pubmed/29578347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.molpharmaceut.7b01013
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados